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Characterization of the Cartilage DNA Methylome in
Knee and Hip Osteoarthritis
Michael D. Rushton,1 Louise N. Reynard,1 Matt J. Barter,1 Ramsay Refaie,2
Kenneth S. Rankin,2 David A. Young,1 and John Loughlin1
Objective. The aim of this study was to character-
ize the genome-wide DNA methylation profile of chon-
drocytes from knee and hip cartilage obtained from
patients with osteoarthritis (OA) and hip cartilage
obtained from patients with femoral neck fracture,
providing the first comparison of DNA methylation
between OA and non-OA hip cartilage, and between OA
hip and OA knee cartilage.
Methods. The study was performed using the
Illumina Infinium HumanMethylation450 BeadChip ar-
ray, which allows the annotation of 480,000 CpG sites.
Genome-wide methylation was assessed in chondrocyte
DNA extracted from 23 hip OA patients, 73 knee OA
patients, and 21 healthy hip control patients with fem-
oral neck fracture.
Results. Analysis revealed that chondrocytes from
the hip cartilage of OA patients and healthy controls
have unique methylation profiles, with 5,322 differen-
tially methylated loci (DMLs) identified between the 2
groups. In addition, a comparison between hip and knee
OA chondrocytes revealed 5,547 DMLs between the 2
groups, including DMLs in several genes known to be
involved in the pathogenesis of OA. Hip OA samples
were found to cluster into 2 groups. A total of 15,239
DMLs were identified between the 2 clusters, with an
enrichment of genes involved in inflammation and im-
munity. Similarly, we confirmed a previous report of
knee OA samples that also clustered into 2 groups.
Conclusion. We demonstrated that global DNA
methylation using a high-density array can be a power-
ful tool in the characterization of OA at the molecular
level. Identification of pathways enriched in DMLs
between OA and OA-free cartilage highlight potential
etiologic mechanisms that are involved in the initiation
and/or progression of the disease and that could be
therapeutically targeted.
Osteoarthritis (OA) is a common degenerative
disease of the synovial joints, characterized by the
gradual thinning and eventual loss of articular cartilage,
which can be accompanied by changes in other joint
tissues (1,2). Age, obesity, and genetic susceptibility are
known OA risk factors (3,4).
Cartilage is made and maintained by a single cell
type, the chondrocyte. The extracellular matrix (ECM)
of cartilage undergoes constant remodeling, with the
chondrocyte responsible for maintaining the balance
between anabolic and catabolic factors (5). In OA,
chondrocytes undergo a phenotypic change, character-
ized by clonal expansion and hypertrophy, accompanied
by a shift in the balance of cartilage homeostasis toward
overall matrix degradation (4).
Since the shift in the homeostasis of the cartilage
ECM principally results from altered gene expression, it
has been hypothesized that epigenetic alterations in
chondrocytes could be a key driver of OA pathogenesis
(6,7). Of the 3 epigenetic modifications, DNA methyl-
ation at CpG sites is by far the most extensively studied
in common diseases. It has long been suspected that
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epigenetics plays a key role in the onset and progression
of common diseases by providing a link between genetic
and environmental risk factors (6,8).
There have been several candidate gene–based
studies investigating the role of DNA methylation in OA
cartilage. For example, it has previously been shown that
up-regulation of the metalloproteinases matrix metallo-
proteinase 3 (MMP-3), MMP-9, MMP-13, MMP-14, and
ADAMTS-4 in OA chondrocytes is mediated by the
demethylation of the promoter regions of the genes
coding for these proteins (9–11). Furthermore, demeth-
ylation of an enhancer region within the nitric oxide
synthase gene leads to increased transcription through
elevated binding of the transcription factor NF-B (12).
It has also been shown that the promoter of IL1B
undergoes demethylation in human articular chondro-
cytes in response to inflammatory cytokine signaling
(11,13). DNA methylation can also modulate OA ge-
netic susceptibility loci, with altered methylation impact-
ing the effect of the OA associated single-nucleotide
polymorphism (SNP) rs143383 on GDF5 expression
(14). The only genome-wide approach to methylation
changes in OA cartilage reported so far was conducted
by Ferna´ndez-Tajes et al (15). Those investigators used
an Illumina Infinium HumanMethylation27 array, which
measures the methylation level at 27,000 CpG sites.
They measured methylation differences between knee
cartilage in 23 OA patients and 18 healthy controls and
discovered 91 differentially methylated loci (DMLs).
Given the clear importance of DNA methyl-
ation in disease and its emerging role in OA, we set out
to characterize the cartilage DNA methylome in OA.
To measure DNA methylation, we used the highest
density array currently available, the Illumina Infinium
HumanMethylation450 BeadChip, which encompasses
480,000 CpG probes throughout the genome. We
conducted the first comparison between OA and healthy
hip chondrocytes, as well as the first comparison be-
tween OA hip and knee chondrocytes. We identified a
series of highly compelling differences relevant to both
the OA disease state and to the joint site studied. We
conclude that the identification of pathways enriched in
DMLs may lead to more effective characterization of
this common arthritis and could offer novel insights into
treatment developments.
PATIENTS AND METHODS
Patients. Cartilage tissue was collected from the hip
joints of patients undergoing hip replacement surgery because
of primary hip OA (n  23) or fracture of the femoral neck
(n  21). Preoperative radiographs of the joints were graded
for their OA status using the Kellgren/Lawrence (K/L) scoring
system (range 0–4, where 1 indicates no OA and 2
indicates OA). Patients with femoral neck fracture had no
radiographic signs of hip OA (K/L score of 0 or 1), with
macroscopically intact cartilage and no lesions. These cartilage
samples served as controls for the hip OA cartilage. Cartilage
tissue was also collected from 73 patients undergoing knee
joint replacement surgery because of primary knee OA. All
OA patients had a K/L score of at least 2, had visible cartilage
lesions, and were screened to exclude OA due to trauma or
other pathologic conditions. The cartilage was collected from
the tibial plateau and from the lateral and medial femoral
condyles. In all OA patients, the cartilage was collected from
sites distal to the OA lesion. The cartilage represented a mix of
superficial, intermediate, and deep layers of the tissue. Sup-
plementary Table 1 (available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
38713/abstract) provides further details regarding the 117
patients studied.
The Newcastle and North Tyneside research ethics
committee granted approval for the study (REC reference
number 09/H0906/72). Informed consent was obtained from
each donor.
Genomic DNA isolation and bisulfite treatment. For
each patient, genomic DNA was isolated from 250 mg of
ground cartilage tissue using an EZNA DNA/RNA isolation
kit (Omega Bio-Tek), as previously described (16). A total of
500 ng of this cartilage genomic DNA was then bisulfite
converted using an EZ DNA methylation kit (Zymo Re-
search), and eluted in 10 l of elution buffer (50 ng/l).
DNA methylation profiling. DNA methylation pro-
filing was carried out on the bisulfite-converted cartilage
DNA by Cambridge Genomic Services, using the Infinium
HumanMethylation450 BeadChip array (Illumina). The raw
data were extracted using GenomeStudio tool (Illumina).
GenomeStudio provides the methylation data as  values:  
M/(M  U), where M represents the fluorescent signal of the
methylation probe and U represents the methylation signal of
the unmethylated probe. The  values range from 0 (no
methylation) to 1 (100% methylation).
Data processing. Processing of the raw methylation
data was performed in R (version 3.0.1) using the Watermelon
package (version 2.12) (17). The data were processed and
normalized as previously described (18). Batch correction of
the samples was performed using the ComBat package in R
(19).
Filtering of methylation data. During normalization of
the  values, probes which had a detection P value greater than
0.01 were removed from the analysis. Since male and female
patients were studied, the sex chromosome probes were also
removed. A total of 19,697 probes were removed with detec-
tion P values greater than 0.01, and 11,713 sex chromosomes
probes were removed. This filtering left a total of 454,167
probes that were used for subsequent analysis.
Differential methylation analysis. To identify DMLs,
the average  value was compared between the groups of
interest (for example, hip cartilage from OA versus femoral
neck fracture patients). F test of equality of variances demon-
strated that there was no significant difference in the variance
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of global methylation between the groups of samples (hip OA
versus femoral neck fracture [P  0.74]; hip OA versus knee
OA [P  0.98]), and so, P values were calculated using a t-test
assuming equal variances. A locus was deemed significantly
differentially methylated if there was at least a 10% difference
in methylation between the 2 groups and had a Benjamini-
Hochberg corrected P value of less than 0.05, as previously
reported (20). Genomic annotation of DMLs was carried out
using the Infinium HumanMethylation450 BeadChip annota-
tion file (http://www.illumina.com).
Pyrosequencing. A total of 500 ng of the cartilage-
extracted genomic DNA was bisulfite converted as above and
eluted in 10 l of elution buffer (50 ng/l). Pyrosequencing
assays for the region of interest were designed using PyroMark
assay design software 2.0 (Qiagen), and sequencing was per-
formed using PyroMark Q24 (Qiagen). The primers used are
listed in Supplementary Table 2 (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38713/abstract). DMLs selected for validation by
pyrosequencing were chosen at random from the list of DMLs
between cartilage samples from the hip of patients with
femoral neck fracture and OA.
Pathway analysis. Gene ontology (GO) analysis was
carried out using human GO term associations (http://
www.geneontology.org/). Enriched GO terms with a
Benjamini-Hochberg corrected P value of less than 0.05 were
deemed significant. The enrichment of GO terms was calcu-
lated using the DAVID bioinformatics database functional
tool (21).
Hierarchical clustering. For all unsupervised cluster-
ing, distances between the samples were measured as the
Euclidean distance and were clustered using the Ward method.
Figure 1. Genome-wide methylation in hip cartilage chondrocyte DNA from patients with femoral neck fracture and patients with osteoarthritis
(OA). a, Unsupervised hierarchical clustering of the global  values in the 23 hip OA samples (red) and the 21 femoral neck fracture samples (blue).
b, Heatmap showing the unsupervised clustering of the 5,322 differentially methylated loci (DMLs) identified between the femoral neck fracture and
hip OA samples. DMLs were defined as those with at least a 10% difference in methylation between the 2 groups and with a Benjamini-Hochberg
corrected P value of less than 0.05. Dendrogram at the top shows the clustering of the samples. Dendrogram at the left shows the clustering of the
loci. The methylation scale is shown to the right of the heatmap (1  100% methylation; 0  no methylation). c, Gene ontology pathway analysis
of the 5,322 DMLs.   P  0.05;   P  0.01;   P  0.001, after Benjamini-Hochberg correction for multiple tests. TGF  transforming
growth factor ; ECM  extracellular matrix.
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Principal components analysis (PCA). PCA was per-
formed with the PCA function of the FactoMineR package in
R, using the default parameters.
RNA isolation and reverse transcription. RNA was
isolated from 250 mg of ground cartilage tissue using an
RNeasy kit (Qiagen). A total of 250 ng of extracted RNA was
DNase treated with 2 units of Turbo DNase (Ambion) and was
reverse transcribed using a SuperScript First-Strand comple-
mentary DNA synthesis kit (Invitrogen).
Relative gene expression. Relative gene expression was
measured by real-time PCR using TaqMan chemistry. Gene
expression analysis was carried out using predesigned primers
and probes (Integrated DNA Technologies); primers and
probes were selected so that all known transcript variants of a
particular gene were measured. Expression of target genes was
measured relative to the housekeeping genes 18S, ribosomal
RNA, GAPDH, and HPRT1. The relative expression of the
target genes was calculated using the 2–Ct method:
2Ct(target gene) 2Ct(target gene)Ct(average of housekeeping genes)]
RESULTS
Comparison of the hip cartilage DNA methylome
between OA patients and controls. Unsupervised hier-
archical clustering revealed that samples from patients
with hip OA and controls with femoral neck fracture
can be largely distinguished by their DNA methylome
(Figure 1a). Two main clusters were clearly apparent.
Cluster 1 contained 11 hip OA samples and 18 femoral
neck fracture samples. These 18 femoral neck fracture
samples clustered separately from the OA hip samples,
with only 1 hip OA sample (sample Hip.4479) among
them. Within cluster 2, there were 12 hip OA samples
and 3 femoral neck fracture samples, with the 3 femoral
neck fracture samples (samples T141, T138, and T132)
clustering separately from the OA samples.
Identification of DMLs between hip cartilage
from OA patients and controls. Given that the unsuper-
vised cluster analysis highlighted that hip OA and fem-
oral neck fracture samples could segregate based on
their methylation profile, a more detailed analysis was
performed to identify individual loci that are differen-
tially methylated between the 2 groups. A total of 5,322
DMLs were identified, of which 2,653 were hypomethy-
lated and 2,669 hypermethylated in OA. Hierarchical
clustering of the DMLs allowed us to largely distin-
guish the control hip samples from the OA hip samples
(Figure 1b). Examples of DMLs within or near the
genes of interest to the OA disease process are listed
in Table 1, and a complete list of DMLs are shown in
Supplementary Table 3 (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38713/abstract).
Noteworthy DMLs included those that occur in
genes coding for proteins associated with degradation of
the ECM, including ADAMTS2, ADAMTS4, ADAMTS5,
ADAMTS10, ADAMTS17, MMP13, and MMP16. DMLs
were also located in other genes involved in the anabolic/
catabolic pathways of cartilage homeostasis, including
ECM1 and CHST11, as well as members of the trans-
forming growth factor  (TGF) signaling pathway,
including ACVR1B, SMAD2, SMAD3, TGFBR2, TGFB1,
and BMP6. We also identified DMLs within genes that
reside within genomic intervals that have been geneti-
Table 1. Genes harboring differentially methylated loci between hip
osteoarthritis (OA) and femoral neck fracture samples
Gene
Mean  value P, after
Benjamini-
Hochberg
correction
Femoral neck
fracture patients
Hip OA
patients
Hypermethylated in OA
ACVR1B 0.42 0.53 0.00091
ADAMTS2 0.47 0.58 0.0081
ADAMTS8 0.49 0.60 0.00045
BMPR1A 0.60 0.70 0.038
BMPR1B 0.35 0.60 0.000031
COL2A1 0.24 0.37 0.010
COL5A3 0.29 0.42 0.000030
COL9A1 0.57 0.69 0.0035
COL9A3 0.27 0.38 0.0091
COL11A2 0.27 0.47 0.000013
COL13A1 0.21 0.31 0.018
IL17B 0.32 0.42 0.0060
MCF2L 0.46 0.56 0.0043
MMP16 0.63 0.75 0.00020
PTHLH 0.15 0.28 0.000030
SMAD2 0.32 0.46 0.0033
SMAD3 0.69 0.81 0.000048
SUPT3H 0.55 0.68 0.0071
TGFB2 0.32 0.47 0.032
TGFBR2 0.61 0.72 0.00011
Hypomethylated in OA
ACVR1 0.87 0.76 0.00096
ADAMTS4 0.65 0.52 0.00040
ADAMTS5 0.75 0.60 0.0000031
ADAMTS10 0.82 0.65 0.00079
ADAMTS17 0.59 0.43 0.00015
BMP1 0.33 0.22 0.00000030
BMP6 0.34 0.22 0.00060
CHST11 0.83 0.70 0.0031
COL1A2 0.58 0.42 0.0022
COL6A3 0.57 0.44 0.00093
COL7A1 0.36 0.24 0.000025
COL8A1 0.80 0.66 0.00055
COL22A1 0.49 0.38 0.0040
ECM1 0.59 0.47 0.00061
FILIP1 0.54 0.37 0.00022
IL4R 0.53 0.34 0.0015
MMP13 0.73 0.60 0.0025
PBRM1 0.83 0.68 0.000017
TGFB1 0.42 0.27 0.031
TGFBR3 0.39 0.28 0.016
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cally associated with OA, including the aforementioned
CHST11 and PBRM1, SUPT3H, FILIP1, and PTHLH
(22). GO term analysis of genes containing DMLs
indicated an enrichment of pathways known to be in-
volved in OA (see Figure 1c for examples), predomi-
nantly pathways involved in regulating the ECM and
collagen synthesis.
Validation of DMLs. Three genes with DMLs
between the hip OA and femoral neck fracture samples
(SIM2, TNXB, and ALX1) were selected for validation
by pyrosequencing (Supplementary Figure 1, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38713/abstract).
This revealed a strong correlation between the methyl-
ation values obtained from the array and those obtained
from pyrosequencing: r2  0.68 for SIM2, r2  0.75 for
TNXB, and r2  0.84 for ALX1.
Methylation of gene promoters and/or enhancers
is known to correlate with decreased gene expression,
whereas methylation within nonenhancer regions of the
gene body correlates with increased gene expression
(23,24). We examined 2 genes (ADAMTS5 and ACVR1)
Figure 2. Segregation of cartilage chondrocyte DNA from patients with hip osteoarthritis (OA) based on the methylation profile. a, Unsupervised
hierarchical clustering of the global  values in the hip OA samples, which revealed 2 distinct clusters. b, Heatmap showing the unsupervised
clustering of the 15,239 differentially methylated loci (DMLs) identified between the 2 hip OA clusters. DMLs were defined as those with at least
a 10% difference in methylation between the 2 groups and with a Benjamini-Hochberg corrected P value of less than 0.05. Dendrogram at the top
shows the clustering of the samples. Dendrogram at the left shows the clustering of the loci. The methylation scale is shown to the right of the
heatmap (1  100% methylation; 0  no methylation). c, Gene ontology pathway analysis of the 15,239 DMLs.   P  0.05;   P  0.01;
  P  0.001, after Benjamini-Hochberg correction for multiple tests. d, Analysis of 4 selected loci found to be differentially methylated in hip
OA versus femoral neck fracture (NOF) samples and between hip OA clusters 1 and 2 (OA hip 1 and 2). Each data point represents a single sample;
horizontal lines and error bars show the mean  SEM.   P  0.05;   P  0.01;   P  0.001, by one-way analysis of variance. Color figure
can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.38713/abstract.
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that contained DMLs within the gene body (nonen-
hancer region) between hip OA and femoral neck
fracture samples. Both showed decreased methylation in
hip OA samples as compared to femoral neck fracture
samples, and we observed a decrease in the expression
of both genes in the hip OA samples (Supplementary
Figure 2a, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38713/abstract.
We also examined 2 genes (LRP5 and CHST11)
that contained DMLs within predicted enhancer re-
gions between hip OA and femoral neck fracture sam-
ples. Both were hypomethylated in hip OA as com-
pared to femoral neck fracture samples and, as expected,
we observed an inverse relationship with the level of
gene expression between the 2 groups (Supplementary
Figure 2b).
Clustering of hip OA cartilage samples based on
their methylome. As noted above, initial unsupervised
clustering of the 454,167 probes indicated that hip OA
samples segregate based on their DNA methylation
profile (Figure 1a). We further investigated this obser-
vation by performing hierarchical clustering of the hip
OA samples, which confirmed the clustering (Figure 2a).
Table 2. Genes harboring differentially methylated loci between the
2 hip osteoarthritis clusters
Gene
Mean  value
P, after
Benjamini-
Hochberg
correctionCluster 1 Cluster 2
Hypermethylated in cluster 2
ACAN 0.68 0.79 0.0035
ADAMTS2 0.23 0.37 0.00093
ADAMTS7 0.41 0.55 0.0020
ADAMTS9 0.23 0.37 0.031
ADAMTS10 0.55 0.66 0.0012
ADAMTS14 0.44 0.59 0.033
BMP2 0.28 0.56 0.00058
BMP4 0.42 0.54 0.0096
BMP6 0.27 0.39 0.029
BMP8A 0.69 0.84 0.0069
BMPR1A 0.32 0.48 0.025
COL2A1 0.21 0.34 0.0011
GDF5 0.66 0.79 0.000078
IL6 0.43 0.58 0.027
IL10 0.15 0.35 0.017
IL16 0.71 0.82 0.035
IL17B 0.41 0.58 0.0017
MCF2L 0.26 0.48 0.0033
MMP2 0.39 0.52 0.00028
MMP20 0.14 0.29 0.025
MMP28 0.25 0.41 0.028
SMAD5 0.62 0.73 0.018
SMAD7 0.44 0.59 0.00019
Hypomethylated in cluster 2
ACVR1 0.83 0.71 0.033
ADAM11 0.41 0.31 0.022
ADAM12 0.89 0.75 0.021
ADAM19 0.82 0.66 0.046
ADAMTS1 0.52 0.32 0.017
ADAMTS5 0.31 0.18 0.0026
ADAMTS6 0.64 0.51 0.026
ADAMTSL2 0.58 0.40 0.016
CHST11 0.43 0.21 0.0052
ECM1 0.55 0.39 0.00042
IL2 0.51 0.34 0.031
IL3 0.52 0.35 0.0028
IL15 0.55 0.40 0.015
IL17C 0.45 0.34 0.032
IL4R 0.47 0.23 0.00035
MMP19 0.39 0.24 0.0045
SMAD3 0.60 0.43 0.020
TGFB1 0.34 0.22 0.032
SMAD3 0.25 0.15 0.048
Table 3. Genes harboring differentially methylated loci between the
2 knee osteoarthritis clusters
Gene
Mean  value
P, after
Benjamini-
Hochberg
correctionCluster 1 Cluster 2
Hypermethylated in cluster 2
ACVR2B 0.52 0.62 0.0000021
ADAMTSL1 0.47 0.59 0.0039
ADAMTSL3 0.61 0.71 0.0000027
BMP2 0.32 0.45 0.000026
BMP5 0.38 0.51 0.0000055
COL2A1 0.31 0.44 0.00000000016
COL6A3 0.18 0.29 0.00000033
FGF1 0.24 0.36 0.0000013
IL10 0.14 0.25 0.000021
IL16 0.44 0.58 0.000000016
IL18 0.29 0.41 0.00020
IL19 0.39 0.49 0.000046
MMP28 0.45 0.56 0.000000064
MTOR 0.24 0.38 0.0000034
SMAD2 0.46 0.58 0.00000011
SMAD7 0.19 0.29 0.000020
TGFB1 0.48 0.62 0.00000096
TGFB2 0.39 0.51 0.00088
Hypomethylated in cluster 2
ACVR1 0.78 0.67 0.0000000081
ADAM12 0.84 0.74 0.000000011
ADAM32 0.77 0.65 0.000016
ADAMTS10 0.70 0.51 0.00000000066
ADAMTS12 0.54 0.44 0.00057
CHST11 0.75 0.64 0.00000021
IL2 0.50 0.39 0.00070
IL4R 0.42 0.27 0.000000000078
IL6R 0.63 0.49 0.000084
MMP19 0.37 0.26 0.000000010
RUNX1 0.65 0.46 0.000000037
RUNX2 0.69 0.55 0.000011
RUNX3 0.71 0.59 0.0000034
SMAD3 0.63 0.48 0.0000000020
TGFBR2 0.67 0.48 0.0000000025
TGFBR3 0.56 0.41 0.0000000023
TIMP2 0.87 0.76 0.000011
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Two clear clusters were apparent, with cluster 1 contain-
ing 11 samples and cluster 2 containing 12. PCA of the
OA hip samples confirmed this clustering (Supplemen-
tary Figure 3, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38713/abstract). There were 15,239 DMLs between
the 2 clusters, with 8,324 hypermethylated and 6,915
hypomethylated in cluster 2. Hierarchical clustering
demonstrated that the 15,239 DMLs could be used to
distinguish between the 2 clusters (Figure 2b). Intrigu-
ingly, GO term analysis of genes containing DMLs
revealed an enrichment of several pathways involved in
the immune response and inflammation (Figure 2c),
including IL2, IL3, IL4, and IL6. There were again
several DMLs in genes involved in TGF signaling and
in genes involved in cartilage degradation and homeo-
stasis (Table 2 and see Supplementary Table 4 for full
list [available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38713/
abstract]).
Figure 2d presents specific examples of CpG sites
that showed significant differences in  values between
OA hip samples from cluster 1 and cluster 2, as well as
the  values for the femoral neck fracture samples,
which showed significant differences between each of
the 2 OA hip clusters. The CpG sites reside at the genes
BMPR1B, ADAMTS5, CHST11, and SOX5.
Clustering of knee OA cartilage samples based
on their methylome. A previous study showed that knee
OA samples also segregate into 2 groups (13). However,
that study was performed with the relatively low-density
Illumina 27K human methylation array. Unsupervised
hierarchical clustering of our 73 knee OA samples also
revealed 2 separate clusters, with 39 samples within
cluster 1 and 34 samples within cluster 2 (Supplementary
Figure 4a, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38713/abstract). PCA confirmed that the samples
split into 2 clusters (Supplementary Figure 5, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38713/abstract).
Comparison between the 2 knee clusters revealed 5,769
DMLs, of which 3,000 were hypermethylated in cluster 2
and 2,769 were hypomethylated in cluster 2. As for the
enrichment observed for the 2 hip OA clusters described
above, there was also enrichment between the 2 knee
OA clusters of genes involved in immune response
pathways (see Supplementary Figure 4b for examples).
Table 3 highlights key examples, and Supplementary
Table 5 provides a full list (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38713/abstract).
Comparison of the DNA methylome between hip
OA and knee OA cartilage. Having demonstrated that
hip OA and knee OA each segregates into clusters, we
next investigated whether there was a commonality of
DMLs accounting for the stratification observed in the
hip clusters and in the knee clusters. A total of 3,496
shared DMLs (23% of hip OA cluster DMLs, 61% of
knee OA cluster DMLs) were identified (data not
shown). GO term analysis again revealed an enrichment
of genes involved in the immune response (data not
shown). However, particularly in the case of the hip OA
samples, a large number of the DMLs did not overlap
between the 2 joints, which suggests that alternative
genes/pathways may be involved in the observed strati-
fication. A full list of the shared DMLs between the hip
OA and knee OA clusters is shown in Supplementary
Table 6 (available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38713/abstract).
We next compared DNA methylation between
hip OA and knee OA samples. A total of 5,547 DMLs
Table 4. Genes harboring differentially methylated loci between hip
and knee osteoarthritis (OA) samples
Gene
Mean  value P, after
Benjamini-
Hochberg
correction
Knee OA
patients
Hip OA
patients
Hypermethylated in hip OA
ADAM12 0.70 0.83 0.00000000015
ADAM7 0.17 0.28 0.000033
ADAMTS2 0.77 0.88 0.00000016
ADAMTS5 0.51 0.66 0.000080
ADAMTS17 0.27 0.42 0.0000049
COL6A3 0.43 0.63 0.00000000083
IL17RD 0.48 0.65 0.000000034
IL18 0.35 0.46 0.0047
IL1RN 0.47 0.59 0.0000016
RUNX3 0.59 0.74 0.000000000025
TGFB2 0.21 0.32 0.00073
Hypomethylated in hip OA
ADAMTS9 0.42 0.31 0.00036
BMP6 0.31 0.19 0.0011
BMP7 0.46 0.33 0.0000022
CHST11 0.65 0.53 0.0000026
COL4A2 0.60 0.44 0.00000020
COL18A1 0.68 0.58 0.00000000018
FGF1 0.66 0.56 0.0084
FGFR3 0.66 0.55 0.00014
GDF5 0.85 0.73 0.000049
IL10 0.69 0.56 0.000018
MCF2L 0.51 0.40 0.0013
PCOLCE 0.46 0.33 0.00015
SMAD7 0.78 0.62 0.0000018
TGFBR2 0.59 0.49 0.0065
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were identified, with 2,598 hypermethylated in hip OA
and 2,949 hypomethylated in hip OA. A large number of
the genes containing DMLs encode proteins that are
involved in development; selected pathways relevant to
OA are shown in Supplementary Figure 4c (available on
the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38713/abstract).
In addition, genes coding for proteins involved in OA
pathogenesis were again represented by the DMLs,
including ADAM12, ADAMTS5, CHST11, GDF5, and
MCF2L (Supplementary Table 7, available on the Ar-
thritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38713/abstract). Several key
DMLs are listed in Table 4.
Analysis of genome features enriched within the
DMLs. It has recently become apparent that the location
of a CpG has important implications in the effect of
DNA methylation on gene expression (24). We there-
fore investigated whether there is enrichment for certain
genome features within the DMLs. We studied all of the
DMLs that we have identified and present those data
here; the same results were obtained when we looked at
the hip DMLs and the knee DMLs separately (data not
shown). Accounting for the distribution of the CpG
probes on the 450 BeadChip array, Supplementary
Figure 6a demonstrates that there was a decrease in
DMLs within CpG islands, but an increase within CpG
shores and shelves. As shown in Supplementary Figure
6b, the increased frequency of DMLs within enhancers
was confirmed.
Recent studies have challenged the dogma that
CpG island–associated promoters are more likely to be
differentially regulated. Instead, it has now become
apparent that relatively CpG-poor regions in distal
regulatory elements are much more likely to show
methylation alterations in response to environmental
effects and that these methylation changes are more
strongly associated with differential gene expression
(25,26). Likewise, our results show an increase in DMLs
within less dense CpG regions.
DISCUSSION
In the present report, we describe the character-
ization of the cartilage chondrocyte DNA methylome in
a cohort of 96 OA patients and 21 non-OA controls. For
the first time, we have characterized the DNA methyl-
ome of OA and non-OA hip chondrocytes and identified
several DMLs between the 2 groups that may play a role
in the disease. Furthermore, we revealed that hip OA
samples can be separated into 2 groups based on their
methylation profile. This has previously been observed
in knee OA and has clear implications for future diag-
nostic and therapeutic approaches to the disease. Simi-
larly, knee OA and hip OA samples have distinct
methylation profiles, emphasizing the importance of
separating a study of OA by skeletal site. Likewise, a
previous microarray study has shown that knee and hip
OA samples show discordance at the gene expression
level (27).
A previous investigation of the cartilage DNA
methylome in knee OA samples used the Illumina
Infinium HumanMethylation27 array (15). By using the
Illumina Infinium HumanMethylation450 array, our
study provides a much more comprehensive analysis.
Not only does this array contain significantly more
probes, it also contains probes within a range of genomic
features, including enhancers, promoters, and the gene
body, that are not covered by the promoter-centric
Infinium HumanMethylation27 array. Including probes
within different genome features is important, as it is
nowwell established that the effect of differential methyl-
ation is dependent on the location of the CpG dinucleo-
tide (23,24,28–30).
Our comparison of the DNA methylome of hip
cartilage samples from OA patients and controls re-
vealed a total of 5,322 DMLs. Several reside in genes
that have previously been shown via candidate gene
studies to be differentially methylated in OA (9,10,31).
However, we identified a large number of DMLs in hip
OA that have not previously been described, including
within genes coding for proteins active in the catabolic
and anabolic pathways of cartilage homeostasis. This
observation suggests that DNA methylation is a key
regulatory step in the shift in the balance of cartilage
maintenance in the direction of overall degradation.
One highly relevant pathway that emerged from
our analysis is the TGF pathway (32). Downstream
signaling of TGF is altered during the development of
OA, with a shift from the anabolic SMAD2/3 pathway to
the catabolic SMAD1/5/8 pathway (33,34). Interestingly,
we observed that both SMAD2 and SMAD3 were differ-
entially methylated in OA patients compared to con-
trols, indicating that epigenetics is a driving force in this
shift. Furthermore, genes encoding receptors of mem-
bers of the TGF superfamily were also differentially
methylated. A role of DNA methylation in switching
TGF signaling is particularly appealing, as the switch is
associated with aging, which in turn, is associated with
aberrant DNA methylation (35,36).
We also observed DMLs that fall within OA
genetic-association signals discovered by the Arthritis
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Research UK Osteoarthritis Genetics (arcOGEN) Con-
sortium and by other studies (22). It will be intriguing to
assess whether the genotype at the associated SNPs
correlates with differences in methylation at CpG sites
encompassed by the association signals. Several of the
genes that contain DMLs within our study have also
been shown to be differentially expressed between hip
OA and femoral neck fracture cartilage in a previous
study, including ACVR1, ADAMTS1, ADAMTS5,
ADAMTS6, BMP6, COL2A1, and FGFR3 (27).
Within our analysis, we observed that 2 clusters
formed within the OA hip samples based on their
genome-wide methylation profiles. Subsequent analysis
revealed 15,239 DMLs between the 2 clusters. There was
a striking enrichment of genes containing DMLs in
pathways involved in the immune response and inflam-
mation. This suggests that inflammation, at least for a
subgroup of OA patients, may play a more integral role
in the disease process than has previously been envi-
sioned. This is consistent with proteomic and transcrip-
tomic data (37). The femoral neck fracture samples also
formed 2 clusters; however, the majority of these (18 of
21 [86%]) grouped together in cluster 1. Nevertheless,
our data may also point to methylation differences
within the cartilage of the femoral neck fracture pheno-
type that may also be informative.
It has previously been shown that knee OA
samples also cluster based on their DNA methylation
profile (13). This result was derived from an analysis of
23 knee OA patients. Our analysis of 73 knee OA
patients revealed the same effect, with 2 distinct clusters
apparent. There were a total of 5,769 DMLs between the
2 groups. This is greater than the 1,357 DMLs discov-
ered previously, which is presumably a reflection of the
larger sample size we used combined with the greater
density of the 450 array. Nevertheless, the observations
were similar to those in the previous report, with an
enrichment of genes coding for proteins involved in the
inflammatory response. However, we identified addi-
tional genes that discriminate between the 2 groups,
including several coding for interleukins, as well as genes
coding for members of the TGF pathway. This clearly
emphasizes the greater sensitivity that is derived from
investigating a larger number of CpG sites in more
patients.
A comparison between the DMLs identified in
the hip cluster and knee cluster analyses revealed an
overlap of inflammatory genes. This indicates that there
is a shared molecular mechanism that can segregate
patients, whether they present with knee OA or with hip
OA. OA is strongly associated with aging, while OA
chondrocytes can acquire a senescent state (38). In the
senescence-associated secretory phenotype (SASP), se-
nescent cells undergo a change in protein expression and
secretory activity (39). Intriguingly, several of the genes
in our study harboring DMLs between the hip OA
clusters and the knee OA clusters code for SASP
proteins, which raises the possibility that in a subset of
samples, the clustering may be partly a result of an SASP
phenotype.
A comparison between the knee and hip OA
samples revealed 5,547 DMLs. A large number of these
were within developmental genes, most notably homeo-
box genes, and in OA pathogenesis and/or cartilage
homeostasis genes. This suggests that there may be
unique pathways that distinguish OA of the knee with
OA of the hip. This is consistent with genetic association
and gene expression studies, which indicate that OA-
associated signals are often joint-specific (22,27).
One of the greatest challenges in epigenetic
studies is in establishing causality. We used cartilage
samples from patients with end-stage OA, and we se-
lected intact cartilage from sites distal to the OA lesion.
An alternative would have been to study cartilage from
the site of the lesion and to compare this with distal
cartilage from the same patient. This may shed light on
key events involved in the latter stages of cartilage
degeneration. If such data become available, it would be
intriguing to compare and contrast DMLs between these
studies and ours as a means of potentially untangling the
key causal and responsive DNA methylation events.
It would also have been interesting to compare
the methylome of knee OA samples with knee control
samples and to further compare any methylation differ-
ences observed with those identified between hip OA
and femoral neck fracture samples. However, this was
not possible due to the lack of a suitable control for the
knee. Another limitation of our study is the older age of
the femoral neck fracture patients compared to the hip
OA patients (average of 12 years), since it is known that
epigenetic changes occur during aging. However, such
epigenetic differences are observed over many years
between young individuals and the elderly (e.g., between
newborns and centenarians) (40). We suspect that the
relatively small difference in the age of the femoral neck
fracture and OA hip samples would have minimal
impact on the cartilage DNA methylome, but we cannot
discount its potential effect.
In conclusion, we demonstrate that OA hip
cartilage chondrocyte DNA can be distinguished from
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healthy hip cartilage chondrocyte DNA by their methyl-
omes. We show that several genes involved in OA-
specific pathways are differentially methylated and may
therefore offer potential therapeutic targets in the treat-
ment of this common disease. In addition, we provide
evidence that DNA methylation profiling can be a
powerful diagnostic tool, allowing the identification of a
subcluster of knee samples and a subcluster of hip sam-
ples characterized by differences in the DNA methyl-
omes of genes coding for inflammatory factors. Analysis
of the DNA methylome is clearly therefore an extremely
useful tool in our efforts to understand the molecular
basis of this complex arthritis.
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